Hard to believe that PGEN traded at $7 two years ago when they announced positive results for AG019 on June 10, 2021.  Of course who knew that the monthly treatment price of insulin would drop 90% from $400 a month to less than $40 a month in the U.S. besides Mabel ?

 

 

Have to believe that fact is what has tabled any further development of / or interest in  AG019.

 

 

Will the publication of an article in a credible scientific journal by Dr. Cliff Allen,  the lead investigator for the PRGN-2012 project,  rally the shares ?   I doubt it.  It might be good for a nickel or two for an hour or two . . . .. . but no rocket launch there :) 

 

 

It would take an announcement of a definitive path forward for rapid regulatory approval for PRGN-2012 to move the stock imho . . . . . .  and HS has been talking about such progress for so long that it's hard to get "excited" about it . . . .. if you know what I mean :)

 

 

The catalyst that I think could give the stock a lift would be the announcement before year end of sale of Exemplar for $40 - $50M.  That would extend the company's financial runway into mid 2025 and remove the threat of another dilutive secondary. 

 

 

And that would give the company time to deliver more compelling data on PRGN-2012 . . .  and maybe even secure a partner for the drug on terms that would open up the runway for development of their CD-19 program,  etc.

 

 

I know I will catch the wrath of Mabel for suggesting that PGEN could rally almost 50% by year end . . . . ..  we all know Mabel recently sold some PGEN at $1.27 . . . . . . and that Mabel posted on the "other board" that he thought TCRT at $.60 had more upside potential than PGEN.

 

 

Could Mabel be wrong ? ? ?  Almost sacriligious to even utter the words :)